TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention
A P2Y12 inhibitor-based monotherapy after a short period of dual antiplatelet therapy is emerging as a plausible strategy to decrease bleeding events in high-risk patients receiving dual antiplatelet therapy after percutaneous coronary intervention. Ticagrelor With Aspirin or Alone in High-Risk Pati...
Enregistré dans:
| Auteurs principaux: | , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Radcliffe Medical Media
2020
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/00b68501fcf04b64ab484ff925adf97a |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|